The Influence of Hepatitis B and C Virus Infections on Patient and Allograft Outcomes in Kidney Transplantation

[Guest guest]

http://www.transplantation-proceedings.org/article/PIIS0041134511002326/abstract\

?rss=yes

TRANSPLANTATION PROCEEDINGS

Volume 43, Issue 3, Pages 850-852 (April 2011)

The Influence of Hepatitis B and C Virus Infections on Patient and Allograft

Outcomes in Kidney Transplantation

M. Uyar, S. Sahin, H. Dheir, A. Gurkan

Abstract

Background

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the most

important causes of chronic liver diseases among end-stage kidney disease

patients. Our aim was to evaluate the influence of HBV and HCV infections on

patient and allograft outcomes after successfull kidney transplantation.

Patients and Methods

We retrospectively analyzed 592 kidney transplantations performed between

December 2008 and August 2010. We compared patient and graft survivals as well

as age, gender, immunosuppression status, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death.

Results

Thirty-two patients (5.4%; group 1) were positive for HCV antibody, whereas 16

(2.7%) were positive for hepatitis B surface antigen (HBsAg) (group 2). Two

patients (0.3%) were positive concurrently for both HCV antibody and HBsAg. Five

hundred forty-two patients (91.6%; group 3) were negative for both. Patients

were divided into groups with respect to viral infection. The groups were

analyzed for age, gender, immunosuppression, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death, as well as patient and graft

outcomes. There were no differences in patient and graft survivals among the

groups. None of the patients showed signs of hepatic failure. No patient or

graft loss was observed among hepatitis groups when compared with disease-free

patients.

Conclusion

Graft and patient survivals were not influenced by HBV and/or HCV infections.

HBV and HCV infections are not contraindications for kidney transplantation.

Ozel Gaziosmanpasa Hastanesi, Department of Kidney Transplantation and

Nephrology, Istanbul, Turkey

Address reprint requests to Murathan Uyar, Ozel Gaziosmanpasa Hastanesi,

Department of Kidney Transplantation and Nephrology, Cukurcesme cad No:51

Gaziosmanpasa, Istanbul, Turkey

PII: S0041-1345(11)00232-6

doi:10.1016/j.transproceed.2011.01.148

© 2011 Elsevier Inc. All rights reserved.

[Guest guest]

http://www.transplantation-proceedings.org/article/PIIS0041134511002326/abstract\

?rss=yes

TRANSPLANTATION PROCEEDINGS

Volume 43, Issue 3, Pages 850-852 (April 2011)

The Influence of Hepatitis B and C Virus Infections on Patient and Allograft

Outcomes in Kidney Transplantation

M. Uyar, S. Sahin, H. Dheir, A. Gurkan

Abstract

Background

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the most

important causes of chronic liver diseases among end-stage kidney disease

patients. Our aim was to evaluate the influence of HBV and HCV infections on

patient and allograft outcomes after successfull kidney transplantation.

Patients and Methods

We retrospectively analyzed 592 kidney transplantations performed between

December 2008 and August 2010. We compared patient and graft survivals as well

as age, gender, immunosuppression status, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death.

Results

Thirty-two patients (5.4%; group 1) were positive for HCV antibody, whereas 16

(2.7%) were positive for hepatitis B surface antigen (HBsAg) (group 2). Two

patients (0.3%) were positive concurrently for both HCV antibody and HBsAg. Five

hundred forty-two patients (91.6%; group 3) were negative for both. Patients

were divided into groups with respect to viral infection. The groups were

analyzed for age, gender, immunosuppression, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death, as well as patient and graft

outcomes. There were no differences in patient and graft survivals among the

groups. None of the patients showed signs of hepatic failure. No patient or

graft loss was observed among hepatitis groups when compared with disease-free

patients.

Conclusion

Graft and patient survivals were not influenced by HBV and/or HCV infections.

HBV and HCV infections are not contraindications for kidney transplantation.

Ozel Gaziosmanpasa Hastanesi, Department of Kidney Transplantation and

Nephrology, Istanbul, Turkey

Address reprint requests to Murathan Uyar, Ozel Gaziosmanpasa Hastanesi,

Department of Kidney Transplantation and Nephrology, Cukurcesme cad No:51

Gaziosmanpasa, Istanbul, Turkey

PII: S0041-1345(11)00232-6

doi:10.1016/j.transproceed.2011.01.148

© 2011 Elsevier Inc. All rights reserved.

[Guest guest]

http://www.transplantation-proceedings.org/article/PIIS0041134511002326/abstract\

?rss=yes

TRANSPLANTATION PROCEEDINGS

Volume 43, Issue 3, Pages 850-852 (April 2011)

The Influence of Hepatitis B and C Virus Infections on Patient and Allograft

Outcomes in Kidney Transplantation

M. Uyar, S. Sahin, H. Dheir, A. Gurkan

Abstract

Background

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the most

important causes of chronic liver diseases among end-stage kidney disease

patients. Our aim was to evaluate the influence of HBV and HCV infections on

patient and allograft outcomes after successfull kidney transplantation.

Patients and Methods

We retrospectively analyzed 592 kidney transplantations performed between

December 2008 and August 2010. We compared patient and graft survivals as well

as age, gender, immunosuppression status, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death.

Results

Thirty-two patients (5.4%; group 1) were positive for HCV antibody, whereas 16

(2.7%) were positive for hepatitis B surface antigen (HBsAg) (group 2). Two

patients (0.3%) were positive concurrently for both HCV antibody and HBsAg. Five

hundred forty-two patients (91.6%; group 3) were negative for both. Patients

were divided into groups with respect to viral infection. The groups were

analyzed for age, gender, immunosuppression, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death, as well as patient and graft

outcomes. There were no differences in patient and graft survivals among the

groups. None of the patients showed signs of hepatic failure. No patient or

graft loss was observed among hepatitis groups when compared with disease-free

patients.

Conclusion

Graft and patient survivals were not influenced by HBV and/or HCV infections.

HBV and HCV infections are not contraindications for kidney transplantation.

Ozel Gaziosmanpasa Hastanesi, Department of Kidney Transplantation and

Nephrology, Istanbul, Turkey

Address reprint requests to Murathan Uyar, Ozel Gaziosmanpasa Hastanesi,

Department of Kidney Transplantation and Nephrology, Cukurcesme cad No:51

Gaziosmanpasa, Istanbul, Turkey

PII: S0041-1345(11)00232-6

doi:10.1016/j.transproceed.2011.01.148

© 2011 Elsevier Inc. All rights reserved.

[Guest guest]

http://www.transplantation-proceedings.org/article/PIIS0041134511002326/abstract\

?rss=yes

TRANSPLANTATION PROCEEDINGS

Volume 43, Issue 3, Pages 850-852 (April 2011)

The Influence of Hepatitis B and C Virus Infections on Patient and Allograft

Outcomes in Kidney Transplantation

M. Uyar, S. Sahin, H. Dheir, A. Gurkan

Abstract

Background

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the most

important causes of chronic liver diseases among end-stage kidney disease

patients. Our aim was to evaluate the influence of HBV and HCV infections on

patient and allograft outcomes after successfull kidney transplantation.

Patients and Methods

We retrospectively analyzed 592 kidney transplantations performed between

December 2008 and August 2010. We compared patient and graft survivals as well

as age, gender, immunosuppression status, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death.

Results

Thirty-two patients (5.4%; group 1) were positive for HCV antibody, whereas 16

(2.7%) were positive for hepatitis B surface antigen (HBsAg) (group 2). Two

patients (0.3%) were positive concurrently for both HCV antibody and HBsAg. Five

hundred forty-two patients (91.6%; group 3) were negative for both. Patients

were divided into groups with respect to viral infection. The groups were

analyzed for age, gender, immunosuppression, pretransplant dialysis duration,

chronic allograft dysfunction, and causes of death, as well as patient and graft

outcomes. There were no differences in patient and graft survivals among the

groups. None of the patients showed signs of hepatic failure. No patient or

graft loss was observed among hepatitis groups when compared with disease-free

patients.

Conclusion

Graft and patient survivals were not influenced by HBV and/or HCV infections.

HBV and HCV infections are not contraindications for kidney transplantation.

Ozel Gaziosmanpasa Hastanesi, Department of Kidney Transplantation and

Nephrology, Istanbul, Turkey

Address reprint requests to Murathan Uyar, Ozel Gaziosmanpasa Hastanesi,

Department of Kidney Transplantation and Nephrology, Cukurcesme cad No:51

Gaziosmanpasa, Istanbul, Turkey

PII: S0041-1345(11)00232-6

doi:10.1016/j.transproceed.2011.01.148

© 2011 Elsevier Inc. All rights reserved.